Robert A Cramer
Overview
Explore the profile of Robert A Cramer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
3856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kordana N, Johnson A, Quinn K, Obar J, Cramer R
Microbiol Mol Biol Rev
. 2025 Feb;
:e0001123.
PMID: 39927770
SUMMARYAdvances in modern medical therapies for many previously intractable human diseases have improved patient outcomes. However, successful disease treatment outcomes are often prevented due to invasive fungal infections caused by...
2.
Morgan S, Nichols D, Ni W, Hong G, Salipante S, Solomon G, et al.
Am J Respir Crit Care Med
. 2024 Aug;
210(9):1155-1158.
PMID: 39189854
No abstract available.
3.
James M, Doss K, Cramer R
Curr Opin Microbiol
. 2024 Jul;
80:102521.
PMID: 39079399
Aspergillus fumigatus is a filamentous fungus abundant in the environment and the most common causative agent of a spectrum of human diseases collectively termed aspergillosis. Invasive pulmonary aspergillosis is caused...
4.
Gluck-Thaler E, Forsythe A, Puerner C, Stajich J, Croll D, Cramer R, et al.
bioRxiv
. 2024 Jul;
PMID: 38979181
Fungal infections are difficult to prevent and treat in large part due to strain heterogeneity. However, the genetic mechanisms driving pathogen variation remain poorly understood. Here, we determined the extent...
5.
Gutierrez-Perez C, Puerner C, Jones J, Vellanki S, Vesely E, Xatse M, et al.
mBio
. 2024 Jun;
15(7):e0116624.
PMID: 38934618
Contemporary antifungal therapies utilized to treat filamentous fungal infections are inhibited by intrinsic and emerging drug resistance. Consequently, there is an urgent need to develop novel antifungal compounds that are...
6.
Desai J, Zarakas M, Wishart A, Roschewski M, Aufiero M, Donko A, et al.
J Clin Invest
. 2024 May;
134(12).
PMID: 38696257
We describe a previously unappreciated role for Bruton's tyrosine kinase (BTK) in fungal immune surveillance against aspergillosis, an unforeseen complication of BTK inhibitors (BTKi) used for treating B cell lymphoid...
7.
Price C, Valls R, Ramsey A, Loeven N, Jones J, Barrack K, et al.
mBio
. 2024 Jan;
15(2):e0314423.
PMID: 38179971
Persons with cystic fibrosis (CF), starting in early life, show intestinal microbiome dysbiosis characterized in part by a decreased relative abundance of the genus is a major producer of the...
8.
Jones J, Morelli K, Vesely E, Puerner C, Pavuluri C, Ross B, et al.
mBio
. 2023 Oct;
14(5):e0151623.
PMID: 37830825
PwCF commonly test positive for pathogenic fungi, and more than 90% of the cystic fibrosis patient population is approved for the modulator treatment, Trikafta. Therefore, it is critical to understand...
9.
James M, Aufiero M, Vesely E, Dhingra S, Liu K, Hohl T, et al.
mSphere
. 2023 Oct;
8(6):e0030523.
PMID: 37823656
can cause a life-threatening infection known as invasive pulmonary aspergillosis (IPA), which is marked by fungus-attributable mortality rates of 20%-30%. Individuals at risk for IPA harbor genetic mutations or incur...
10.
Puerner C, Vellanki S, Strauch J, Cramer R
Annu Rev Microbiol
. 2023 Sep;
77:403-425.
PMID: 37713457
Fungal-mediated disease progression and antifungal drug efficacy are significantly impacted by the dynamic infection microenvironment. At the site of infection, oxygen often becomes limiting and induces a hypoxia response in...